Federal Service on Surveillance in Healthcare and Social Development authorized Congenix to conduct the clinical trials in 600 patients with tinea pedis. 24 Russian sites in Moscow, St. Petersburg, Krasnodar, Rostov-na-Donu and other regions will participate in this study.
